Joshua Fitch, Senior Editor

Findings show that that feeding mode is by far the most defining factor for microbial composition," wrote the study authors.

A JAMA Pediatrics study found 37% of adolescents with gender dysphoria began hormone therapy within 2 years, highlighting barriers and inequities in care.

An interactive text message program boosted vaping cessation rates by 35% among adolescents compared to a control group, a JAMA study found.

The approval is indicated for adult and pediatric patients who weigh at least 88 lbs (40 kg).

Among children born in 2020, vaccination coverage was 4 to 14 percentage points lower among those who were eligible for VFC versus non-eligible children.

How can tablet use contribute to expressions of anger and frustration among children aged 3.5 to 5.5 years?

Findings suggest outdoor interventions should focus on effective outdoor exposure patters to prevent myopia in children.

Lynn Malec, MD, joined us to discuss the phase 3 XTEND-Kids study of ALTUVIIIO in pediatric patients with hemophilia A.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The approval is indicated for adult and pediatric patients who weight at least 66 pounds (30 kilograms).

Digital tools like health apps, texts, and telemedicine show promise in managing childhood obesity, but require sustained engagement for long-term impact.

Digital therapeutics help kids build emotional regulation and coping skills, supporting pediatric care while waiting for specialized mental health services.

Suicide was among the top 9 leading causes of death for people aged 10 to 64 years, and was the second leading cause of death for individuals aged 10 to 14 years and 25 to 34 years in 2022.

Current treatment is primarily supportive care consisting of increased fluid intake to dilute oxalate in the urine, along with pyridoxine, or vitamin B6, to reduce oxalate production.

The formula company issued a recall of the products on May 24, 2024, though they were not in compliance with all of the FDA’s infant formula regulations.

A pair of medical directors involved in the transplant clinical space provide commentary on heart and lung transplants in the pediatric population.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Using school-based approaches and staying in close contact with school personnel can increase overall care for the child.

Nine of 32 (28.1%) patients in the mitapivat arm achieved a transfusion reduction response compared to 11.8% of patients in the placebo arm.

Diamyd to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2 was granted Fast Track designation by the FDA in February 2024.

Erica Prochaska, MD, highlights a recent study that aimed to estimate the rate of HOB among infants admitted to the NICU, measure the association of HOB risk with birth weight group and postnatal age, and estimate HOB-attributable mortality.

With the expanded label, Palforzia is now approved to treat individuals aged 1 to 17 years with a confirmed peanut allergy diagnosis, after the treatment was originally approved in 4-to-17-year-olds in January 2020.

The extended label will allow patients to begin SCIg therapy without first having intravenous administration.

"Taken together, our findings suggest the relative protection associated with having a mother versus father with type 1 diabetes is a long-term effect that extends into adult life," stated study investigators.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Overall, mortality rates among youth in the United States were higher than 16 comparison countries used in the study.

From baseline to final assessment, all 7 matched cerliponase alfa-treated children under 3 years of age maintained a motor score of 3, representing a "grossly normal gait, signifying a delay in disease onset," stated BioMarin.

Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

Merck announced clesrovimab met all primary safety and efficacy endpoints, with additional detailed findings to be presented at an upcoming scientific congress.